[go: up one dir, main page]

WO2006003383A1 - Préparation ophtalmique oculaire - Google Patents

Préparation ophtalmique oculaire Download PDF

Info

Publication number
WO2006003383A1
WO2006003383A1 PCT/GB2005/002537 GB2005002537W WO2006003383A1 WO 2006003383 A1 WO2006003383 A1 WO 2006003383A1 GB 2005002537 W GB2005002537 W GB 2005002537W WO 2006003383 A1 WO2006003383 A1 WO 2006003383A1
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
volume
potassium
sodium
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2005/002537
Other languages
English (en)
Inventor
Pravin G. Patel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ACCUMED Ltd
Original Assignee
ACCUMED Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ACCUMED Ltd filed Critical ACCUMED Ltd
Publication of WO2006003383A1 publication Critical patent/WO2006003383A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/58—Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/738—Rosa (rose)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/85—Verbenaceae (Verbena family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Definitions

  • This invention relates to ' ophthalmic eye preparations comprising herbal extracts or their synthetic equivalents.
  • Ophthalmic eye preparations are well known in the art and are generally formulated using pharmaceutical chemicals and drugs for the treatment of eye diseases.
  • pharmaceutical chemicals and drugs for the treatment of eye diseases.
  • the extensive use of contact lenses and refractive surgery has created a demand for eye drops that are safer to use in the long term.
  • the use of synthesised chemicals and drugs as eye drops tends to result in increased side effects and can also cause immunity towards these drugs.
  • the present invention seeks to solve these problems by providing herbal formulations that can be used daily without any significant side effects or adverse interactions with existing medication.
  • Ophthacare An example of previously known herbal ophthalmic eye preparations is the product "Ophthacare” , eye drops sold by the Himalaya Drug Company of India. According to Himalaya's product literature Ophthacare possesses antimicrobial, anti-inflammatory and analgesic qualities and is effective in the management of infective and inflammatory eye disorders. It also claims to relieve congestion and asserts to be beneficial in eyestrain.
  • Ophthacare The ingredients of Ophthacare are stated to be extracts of Carum copticum (6.00%), Terminalia belerica (6.50%) , Emblica officinalis (13.00%), Curcuma longa (13.00%), Ocimum Sanctum (13.00%), Rosa Datnascena (11.00%), Cinnamomum camphora (0.50%) and Meldespumatum (37.-00%)
  • the ophthalmic eye preparations of the present invention improve on the prior art by comprising a novel combination of the extracts from 17 herbs, or the synthetic equivalents of the extracts, in therapeutically effective amounts.
  • the preparations result in unexpectedly improved treatment of various eye diseases dry eye syndrome and the wetting and lubricating of eyes.
  • the preparations are suitable for use with or without contact lenses.
  • the herbs are picked, washed and weighed for processing.
  • the weighed herbs are then enclosed in a high-pressure vessel, through which steam is passed, thereby extracting the herbal oils.
  • the steam extraction procedure produces the oils in the form of concentrated oil/water mixtures.
  • the extract is then checked for its composition and sterility.
  • Ocimum sanctum (Tulsi) anti-inflammatory and anti ⁇ microbial, 5-20%
  • Curcuma longa (Haridra) - anti-inflammatory (comparable to hydrocortisone acetate and phenylbutazone) and anti ⁇ microbial (comparable to penicillin and streptomycin on gram +ve and gram -ve bacteria) , 5-18% Carum copticum (Yamani) - anti -bacterial (against
  • Salmonella typhi Salmonella typhi , Micrococcus pyogenes and Escherichia coli) , 0 . 5-5%
  • Terminalia belerica (Vibhitaka) - anti-bacterial (against Micrococcus pyogenes and E. coli) , 2-7.5%
  • Embilica officinalis (Dhatriphala) - anti-inflammatory and cooling effect, 3-10%
  • Terminalia chebula (Haritaki) - astringent and anti ⁇ inflammatory, 2-7.5% Camphora officinarum (Kapoor) - anti-bacterial (against several gram +ve and gram -ve bacteria) , 1-5%
  • Vitex negundo (Nirgundi) - antiseptic and anodyne, 2-7.5% Moringa pterygosperma (Sobhajana) - analgesic, 2-7.5%
  • Boerhaavia diffusa (Punarnava) - anti-inflammatory, 5-10%
  • Rosa damascena (Satapatri) - astringent and cooling, 5- 10%
  • the formulations also include a sequestering or chelating agent, which is preferably present at approximately 0.01- 2% by volume.
  • the preferred sequestering agents are ethylenediaminetetraacetic acid (EDTA) and its salts, with the disodium salt, disodium edetate, being especially preferred.
  • the preparations may also include buffering agents and tonicity adjusting agents.
  • the buffering agents can be used to buffer or adjust the pH of the solution. Examples of suitable buffering agents include alkali metal salts such as potassium or sodium carbonates, acetates, borates, phosphates, citrates and hydroxides or weak acids such as acetic, boric and phosphoric acids. Preferably, buffering agents are present at approximately 0.01-2.5% by volume.
  • tonicity adjusting agents examples include sodium and potassium chloride, and those materials listed as buffering agents. Tonicity agents may be employed in an amount effective to adjust the osmotic value of the final solution to approximate that of human tears, generally at about 0.01-2.5%.
  • the preparations may include wetting agents or viscosity modifiers.
  • suitable wetting agents and viscosity modifiers include sodium hyluronate; cellulose derivatives such as cationic cellulosic polymers, hydroxypropyl methylcellulose, hydroxyethylcellulose and methylcellulose; and polyols such as polyethylene glycol, glycerine, polyethylene oxide containing polymers, polyvinyl alcohol and polyvinyl pyrrolidone.
  • Such additives are preferably present at approximately 0.01-1.5% by volume.
  • Preservatives may also be added to the formulation.
  • suitable preservatives include polyhexamethylene biguanide, sorbic acid, benzalkonium chloride and phenyl mercuric nitrate.
  • the remainder of the composition is water.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

Cette invention se réfère á une préparation ophtalmique oculaire comprenant des extraits d'herbes ou leurs équivalents synthétiques et un procédé pour leur production. La préparation comprend ocimum sanctum (5-20 %), curcuma longa (5-18 %), carum copticum (0.5-5%), terminala belerica (2-7.5 %), embilica officinalis (3-10 %), terminala chebula (2-7.5 %), camphora officinarum (1-5 %), mentha sylvestries (0.5-5 %), Eletteria Cardamomum (2-7.5 %), santalum album (2-7.5 %), santalum rubrum (2-7.5 %), azadirachta indica (2-7.5 %), vitex negundo (2-7.5 %), moringa pterygosperma (2-7.5 %), eclipta alba (2-7.5 %), boerhaavia diffusa (5-10 %) et rosa damascena (5-10 %) , les quantités préférées des extraits d'herbes en pourcentage par volume étant données entre parenthèse.
PCT/GB2005/002537 2004-07-01 2005-06-29 Préparation ophtalmique oculaire Ceased WO2006003383A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0414772.4 2004-07-01
GB0414772A GB2415902A (en) 2004-07-01 2004-07-01 Ophthalmic eye preparation

Publications (1)

Publication Number Publication Date
WO2006003383A1 true WO2006003383A1 (fr) 2006-01-12

Family

ID=32843407

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2005/002537 Ceased WO2006003383A1 (fr) 2004-07-01 2005-06-29 Préparation ophtalmique oculaire

Country Status (2)

Country Link
GB (1) GB2415902A (fr)
WO (1) WO2006003383A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2901130A1 (fr) * 2006-05-22 2007-11-23 Oreal Preparation d'une formulation a partir d'un fluide sous pression d'un agent cosmetique et d'un hydrotrope cationique procede de traitement la mettant en oeuvre
FR2901125A1 (fr) * 2006-05-22 2007-11-23 Oreal Preparation d'une formulation a partir d'un fluide sous pression, d'un agent cosmetique et d'un hydrotrope hydroxyle, procede de traitement la mettant en oeuvre
FR2901131A1 (fr) * 2006-05-22 2007-11-23 Oreal Preparation d'une formulation a partir d'un fluide sous pression, d'un agent cosmetique et d'un hydrotrope anionique, procede de traitement la mettant en oeuvre
WO2010128486A2 (fr) 2009-05-07 2010-11-11 Stefano Sebastiani Préparation ophtalmique pour le traitement et la prévention du ptérygion
EP2182963A4 (fr) * 2007-07-19 2011-05-18 Delhi Inst Of Pharmaceutical Sciences And Res Dipsar Composition à base d'herbes comprenant des extraits de foeniculum vulgare, murraya koenigii et triphala
CN102176920A (zh) * 2008-11-17 2011-09-07 莱拉制药用品私营有限责任公司 姜黄素及其用于治疗眼科疾病的方法
US8441863B2 (en) 2010-06-15 2013-05-14 Stmicroelectronics S.R.L. Non-volatile memory device with reconnection circuit
KR20200023061A (ko) * 2018-08-24 2020-03-04 한국과학기술연구원 가자육 추출물 포함하는 안구 건조증을 예방 또는 치료하는데 사용하기 위한 약학적 조성물 및 그 용도
JP2023009849A (ja) * 2021-07-08 2023-01-20 日本メナード化粧品株式会社 ドライアイ改善剤

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2905862A1 (fr) * 2006-09-20 2008-03-21 Oreal Procede de preparation d'une composition ayant des proprietes antibacteriennes
WO2010070675A2 (fr) * 2008-12-01 2010-06-24 Laila Pharmaceuticals Pvt. Ltd Formulation(s) topique(s) destinée(s) au traitement de l'inflammation, d'affections cutanées, de maladies des muqueuses et autres maladies associées à celles-ci

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003080091A1 (fr) * 2002-03-27 2003-10-02 All India Institute Of Medical Sciences Formulation ophtalmique a base d'herbes medicinales pour prevenir la cataracte

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003080091A1 (fr) * 2002-03-27 2003-10-02 All India Institute Of Medical Sciences Formulation ophtalmique a base d'herbes medicinales pour prevenir la cataracte

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BISWAS N R ET AL: "Comparative randomised controlled clinical trial of a herbal eye drop with artificial tear and placebo in computer vision syndrome.", JOURNAL OF THE INDIAN MEDICAL ASSOCIATION. MAR 2003, vol. 101, no. 3, March 2003 (2003-03-01), pages 208 - 209 , 212, XP009054489, ISSN: 0019-5847 *
BULLETIN OF TAIWAN FORESTRY RESEARCH INSTITUTE NEW SERIES, vol. 5, no. 1, 1990, pages 45 - 52, ISSN: 1010-5204 *
CAROLINA ET AL: "Extraction of essential oil and pigments from curcuma longa [L.] by steam distillation and extraction with volatile solvents", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 26, no. 2, April 2004 (2004-04-01), XP018000152 *
DAS G K ET AL: "Comparative double masked randomised placebo controlled clinical trial of a herbal eye drop preparation in trachoma and conjunctivitis.", JOURNAL OF THE INDIAN MEDICAL ASSOCIATION. OCT 1995, vol. 93, no. 10, October 1995 (1995-10-01), pages 383 - 384, XP009054491, ISSN: 0019-5847 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1990, SHIEH J-C ET AL: "ESSENTIAL OIL YIELD AND COMPONENT VARIATION FROM SANTALUM-ALBUM WOOD OF DIFFERENT AGE IN TAIWAN", XP002347044, Database accession no. PREV199090098697 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; June 2001 (2001-06-01), BASIM E ET AL: "Antibacterial effect of essential oil produced by Rosa damascane on Xanthomonas axonopodis pv. vesicatoria", XP002347043, Database accession no. PREV200100403991 *
MITRA S K ET AL: "ANTI-INFLAMMATORY, ANTIOXIDANT AND ANTIMICROBIAL ACTIVITY OF OPHTHACARE BAND, AN HERBAL EYE DROPS", PHYTOMEDICINE, GUSTAV FISCHER VERLAG, STUTTGART, DE, vol. 7, no. 2, 2000, pages 123 - 127, XP009008101, ISSN: 0944-7113 *
MUKHERJI R ET AL: "THERAPEUTIC EFFICACY OF A NEW HERBAL EYE DROP FORMULATION", JOURNAL OF THE INDIAN MEDICAL ASSOCIATION, INDIAN MEDICAL ASSOCIATION, CALCUTTA, IN, vol. 83, no. 7, 1985, pages 237 - 239, XP009008106, ISSN: 0019-5847 *
PHYTOPATHOLOGY, vol. 91, no. 6 Supplement, June 2001 (2001-06-01), JOINT MEETING OF THE AMERICAN PHYTOPATHOLOGICAL SOCIETY, THE MYCOLOGICAL SOCIETY OF AMERICA, AND THE; SALT LAKE CITY, UTAH, USA; AUGUST 25-29, 2001, pages S6, ISSN: 0031-949X *
SINGH K P: "RECENT TRENDS IN PRODUCTION METHODS OF ESSENTIAL OILS", INDIAN PERFUMER, vol. 34, no. 1, 1990, pages 64 - 70, XP009054656, ISSN: 0019-607X *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2901130A1 (fr) * 2006-05-22 2007-11-23 Oreal Preparation d'une formulation a partir d'un fluide sous pression d'un agent cosmetique et d'un hydrotrope cationique procede de traitement la mettant en oeuvre
FR2901125A1 (fr) * 2006-05-22 2007-11-23 Oreal Preparation d'une formulation a partir d'un fluide sous pression, d'un agent cosmetique et d'un hydrotrope hydroxyle, procede de traitement la mettant en oeuvre
FR2901131A1 (fr) * 2006-05-22 2007-11-23 Oreal Preparation d'une formulation a partir d'un fluide sous pression, d'un agent cosmetique et d'un hydrotrope anionique, procede de traitement la mettant en oeuvre
EP2182963A4 (fr) * 2007-07-19 2011-05-18 Delhi Inst Of Pharmaceutical Sciences And Res Dipsar Composition à base d'herbes comprenant des extraits de foeniculum vulgare, murraya koenigii et triphala
CN102176920A (zh) * 2008-11-17 2011-09-07 莱拉制药用品私营有限责任公司 姜黄素及其用于治疗眼科疾病的方法
WO2010128486A2 (fr) 2009-05-07 2010-11-11 Stefano Sebastiani Préparation ophtalmique pour le traitement et la prévention du ptérygion
US8441863B2 (en) 2010-06-15 2013-05-14 Stmicroelectronics S.R.L. Non-volatile memory device with reconnection circuit
KR20200023061A (ko) * 2018-08-24 2020-03-04 한국과학기술연구원 가자육 추출물 포함하는 안구 건조증을 예방 또는 치료하는데 사용하기 위한 약학적 조성물 및 그 용도
KR102159343B1 (ko) 2018-08-24 2020-09-23 한국과학기술연구원 가자육 추출물 포함하는 안구 건조증을 예방 또는 치료하는데 사용하기 위한 약학적 조성물 및 그 용도
US11058736B2 (en) * 2018-08-24 2021-07-13 Korea Institute Of Science And Technology Method of treating dry eye syndrome using pharmaceutical composition having extract of Terminalia chebula or fraction thereof
JP2023009849A (ja) * 2021-07-08 2023-01-20 日本メナード化粧品株式会社 ドライアイ改善剤
JP7690195B2 (ja) 2021-07-08 2025-06-10 日本メナード化粧品株式会社 ドライアイ改善剤

Also Published As

Publication number Publication date
GB0414772D0 (en) 2004-08-04
GB2415902A (en) 2006-01-11

Similar Documents

Publication Publication Date Title
US4607038A (en) Ophthalmic pranoprofen compositions
US10568966B2 (en) Formulation for topical wound treatment
CN106334067B (zh) 含银离子抗菌剂的妇科凝胶、制备方法及应用
DK2613793T3 (en) NOSE SPRAY
JPH10298096A (ja) 相乗的草本抽出物
WO2006003383A1 (fr) Préparation ophtalmique oculaire
KR20170036058A (ko) 코 적용을 위한 시네올-함유 조성물
JP6975274B2 (ja) 局所粘膜用水性組成物
CA2872210A1 (fr) Compositions pharmaceutiques topiques comprenant de la terbinafine et de l'uree
CN114796038A (zh) 一种快速祛痘杀菌除螨组合物及其制备方法和应用
CN105726416A (zh) 一种驱蚊消肿止痒凝露
CN108451799A (zh) 一种洗手液及其制备方法
EP3664818A2 (fr) Compositions de décongestionnant nasal comprenant du dexpanthénol et du hyaluronate de sodium
KR101862628B1 (ko) 피부용 윤활제 조성물 및 그 제조방법
CN110917076A (zh) 儿童植物沐浴液
EP3129031B1 (fr) Composition utilisée pour le traitement des troubles gastriques
US20170020946A1 (en) Analgesic compositions and methods of use
CN116159018B (zh) 一种新型外用溴莫尼定凝胶剂
CN112535708A (zh) 一种含妥布霉素和中药提取物的凝胶组合物及其制备方法
CN107149611B (zh) 一种蒙药鼻炎喷雾剂及其制备方法
CN111991289A (zh) 一种抑菌抗炎组方及抑菌抗炎牙膏
EP1210945B1 (fr) Composition pharmaceutique anti-artériosclérotique
RU2292198C1 (ru) Средство лечения грибковых заболеваний кожи широкого спектра действия
CN115990196A (zh) 一种含大麻二酚的抑菌组合物及其制备方法和应用
CN110559343A (zh) 一种睑板腺清洁液

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase